Riskpilot← Back to searchSign inGet full accessViroPharma AB
ABDissolvedOrg 5568636350Activities of holding companies · NACE 6420Est. 20110 employees
Revenue 2021
SEK 0
EBITDA margin
—
Equity ratio
90.9%
Financial strength
Net profit 2021
SEK -17K
+32% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | — | — |
| Net profit | SEK -17K | +32% |
| Total assets | SEK 113,3M | +0% |
| Equity | SEK 102,9M | +0% |
| Employees | 0 | — |
Legal name
ViroPharma AB
Org number
5568636350
Legal form
Aktiebolag
NACE code
6420 · Activities of holding companies
Founded
7 september 2011
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolaget ska bedriva forskning, utveckling, utbildning, marknadsföring och försäljning inom det medicinska området och förvalta bolag som bedriver sådan verksamhet samt idka därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — | — | — |
| EBITDA | 65 006 | — | −174 | −149 | 89 | — | — |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| EBIT | 65 006 | 0 | −174 | −149 | 89 | 0 | 0 |
| Net financials | −18 040 | −2 | — | — | −17 | −25 | −23 |
| Profit before tax | 46 966 | −2 | −174 | −149 | 72 | −25 | −17 |
| Tax | −45 | −7 | −0 | −1 | −0 | −0 | −0 |
| Net profit | 46 921 | −9 | −174 | −150 | 72 | −25 | −17 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|---|
| Total assets | 120 150 | 120 152 | 120 150 | 120 150 | 120 150 | 113 250 | 113 250 |
| Equity | 103 205 | 103 196 | 103 021 | 102 873 | 102 944 | 102 920 | 102 903 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 16 945 | 16 956 | 17 127 | 17 277 | 17 206 | 10 330 | 10 347 |
| Total debt | 16 945 | 16 956 | 17 127 | 17 277 | 17 206 | 10 330 | 10 347 |
EBITDA margin
0.0%
This company
15.8%
Market median
-100% vs market
20152021
Equity ratio
90.9%
This company
38.2%
Market median
+138% vs market
20152021
Return on equity
-0.0%
This company
18.4%
Market median
-100% vs market
20152021
Net profit margin
-1700000.0%
This company
8.1%
Market median
-20987754% vs market
20152021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20152021
Debt / equity
0.10×
This company
0.62×
Market median
+84% vs market
20152021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AL Chief Auditor | Chief Auditor | 2021 | — | — |
AJ Chief Auditor | Chief Auditor | 2022 | — | — |
RH Chief Auditor | Chief Auditor | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ViroPharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ann Louise Ronquist | Chief Auditor | 0 companies |
| Anders Joakim Toivo Taaler | Chief Auditor | 0 companies |
| Resul Hamurcu | Chief Auditor | 0 companies |
| Jacob Fredrik Westin | Board of Directors | 0 companies |
| Sofia Therese Hultman | Board of Directors | 0 companies |
| Vatroslav Mateljic | Chairman | 0 companies |